SuperworthLyell Immunopharma market cap LYEL
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $230.1M
- Highest close in our data
- $4.3B
- Sep 2021
Lyell Immunopharma is worth $230.1M at the close on Oct 23, 2026, at $9.39 a share.
That is down 32% over the last year and down 93% over five years.
Its highest close in our data was $4.3B in Sep 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $230.1M | $199M | $614.9M | −69% |
| 2025 | $744.5M | $118.1M | $744.5M | +310% |
| 2024 | $181.5M | $171M | $780.1M | −63% |
| 2023 | $488.6M | $359M | $873.6M | −44% |
| 2022 | $865.2M | $760.4M | $1.9B | −54% |
| 2021 | $1.9B | $1.9B | $4.3B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Lyell Immunopharma's size, closest first, today.
| Company | Market cap |
|---|---|
| LYELLyell Immunopharma | $230.1M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| LFVNLifevantage | $73.4M |
| COLLCollegium Pharmaceutical | $747.5M |
| SPROSpero Therapeutics | $64.6M |
| ABUSArbutus Biopharma | $831M |
| Peer median | $570.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Lyell Immunopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.